All Drug Development articles – Page 29
-
ArticleThe promise of 3A5C7 mAb in the treatment of morphine tolerance
Morphine is a frequently used analgesic that activates the mu-opioid receptor (MOR), which has prominent side effects of tolerance. A monoclonal antibody (mAb) precisely targeting MOR, named as 3A5C7, was developed to treat morphine tolerance by enhancing morphine-induced MOR endocytosis via GRK2/β-arrestin2 pathway. In this Q&A session with Dr Jia-Jia ...
-
ArticleWomen in Stem with Dr Mrunal Jaywant
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. We had the privilege of interviewing Dr Mrunal Jaywant, Vice President of R&D at USP India. At USP India, Dr Jaywant oversees the Compendial Development, the Synthetic Chemistry, ...
-
ArticleTransforming cancer treatment for greatest impact
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.
-
ArticleGrowth hormone’s influence on neuropsychiatric disorders
The discovery of a mechanism involving anxiolytic effects of GH may lead to the development of new classes of anxiolytic drugs.
-
ArticleThe science of ageing and restoring healthspan
Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. Life Biosciences are specifically focused on restoring and prolonging one’s ...
-
ArticleAllosteric control sites in KRAS protein found
The first complete control map for any protein has been made for KRAS, and four potential drug targets have been discovered.
-
WebinarAdvancing therapeutics targeting cytokines with functional cell-based assays
Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.
-
NewsTargets for pancreatic cancer treatment found
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
-
ArticleWomen in STEM with Dr Catherine Sheehan
In this special December edition of Women in STEM, we are privileged to feature Dr Catherine Sheehan, a distinguished figure whose journey in the field of STEM has been marked by passion, resilience, and impactful contributions. We explore her experiences, challenges faced, and the transformative impact of her work in ...
-
NewsPotential small molecule drug could treat multiple sclerosis
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
-
ArticleWomen in Stem with Andrea Pfeifer
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership, ...
-
NewsNew method to develop therapeutics for autoimmune diseases
A technique that can sort millions of CRISPR-edited cells based on their secretion patterns has been developed to treat autoimmune diseases.
-
News
Improving treatment response to KRAS inhibitors
Eliminating AT1-like cells in experimental models has shown potential to improve KRAS inhibitor treatment for lung adenocarcinoma.
-
Article
Natural killer cells: Looking good for cancer therapy
The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data, but is this belief at the present stage of development of the immune therapy field?
-
ArticleBreaking down barriers across the DMTA cycle
In this article, David Bardsley, Commercial Director, and Nick Foster, Vice President of Discovery CRO at Cresset, explore the challenges that occur when approaching drug discovery in silos and how harnessing advances in technology can help to overcome them.
-
ArticleThe power of combinations in blood cancers
Haematology research is a cradle of innovation, with many firsts in therapeutic approaches utilising the latest technology for the treatment of blood cancers. Anas Younes, Senior Vice President, Head of Haematology Oncology Research and Development at AstraZeneca, envisions a future where potential cures are within reach for more blood cancers ...
-
ArticlePatient-derived organoids in disease modelling
In an exclusive interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
-
ArticleSino Biological: new US centre for bioprocessing
Sino Biological are pleased to announce the formal opening of its new center for Bioprocessing (C4B) in Houston, Texas USA at Levit Green, adjacent to the world-renowned Texas Medical Center.
-
ArticleAntibody-drug conjugates payloads: then, now and next
Dr Nicolas Camper at CDMO Abzena and colleagues offer insight into the landscape of antibody-drug conjugates and how the therapy is evolving.
-
ArticleAddressing increasingly resistant drugs by infectious agents
Infectious agents’ drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.